In addition, serum IL‐6 levels in patients without EMD were lower than those in the other two groups, indicating that attention should be paid to potential side effects in R/R MM patients in the EM‐E and EM‐B groups during anti‐BCMA CAR‐T cell therapy. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.